Masami Nakane

This inventor holds 18 USPTO granted patents, primarily in Quinuclidine Derivatives. Top assignees: Pfizer Corporation, Other. Active years: 1991-2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masami Nakane. Retrieved from https://idiyas.com/inventor/masami-nakane-7mwo8wz2

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18

% Patents Active = 100.0

Average Co-Inventor Count = 4.1

ph-index = 7

Forward Citations = 125(Granted Patents)

Location History:

Aichi, JP (1995 - 1996)
Showakyu, JP (1998 - 1999)
Nagoya, JP (1991 - 2000)
Showakyu, Nagoya 466, JP (2001)

Company Filing History:

17 out of 4,489

Pfizer Corporation

patents

1 out of 834,601

Other

patents

Years Active: 1991-2001

Loading Chart...

Areas of Expertise:

Quinuclidine Derivatives

Azaheterocycles

Substance P Antagonists

Aminobenzosultam Derivatives

Hydroxyureas

Indole Derivatives

Antiallergy Agents

Antiinflammatory Compounds

Benzoxazolinones

Benzoxazolones

Non-aromatic Heterocycles

Lipoxygenase Inhibitors

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6222038 - Quinuclidine derivatives (2001-04-24),

2. 6083943 - Substituted azaheterocyclecarboxylic acid (2000-07-04),

3. 5939433 - Quinuclidine derivatives (1999-08-17),

4. 5886009 - Quinuclidine derivative as a substance P antagonist (1999-03-23),

5. 5852038 - Substituted 3-aminoquinuclidines (1998-12-22),

6. 5837711 - Substituted quinuclidines as substance P antagonists (1998-11-17),

7. 5807867 - Quinuclidine derivatives (1998-09-15),

8. 5721255 - Substituted benzylamino nitrogen containing non-aromatic heterocycles (1998-02-24),

9. 5716965 - Substituted 3-aminoquinuclidines (1998-02-10),

10. 5681858 - Cycloalkyl hydroxyureas (1997-10-28),

11. 5569662 - Quinuclidine derivatives as substance P antagonists (1996-10-29),

12. 5504095 - Aminobenzosultam derivatives as lipoxygenase inhibitors (1996-04-02),

13. 5464849 - N-hydroxyurea derivatives as antiallergy and antiinflammatory agents (1995-11-07),

14. 5290788 - Indole derivatives as antiallergy and antiinflammatory agents (1994-03-01),

15. 5256789 - Antiinflammatory hydroxamic acids and N-hydroxyureas (1993-10-26),

Title: Masami Nakane: Innovator in Pharmaceutical Chemistry

Introduction

Masami Nakane is a prominent inventor based in Nagoya, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of 18 patents to his name, Nakane's work has had a substantial impact on medical science.

Latest Patents

Among his latest patents, Nakane has developed quinuclidine derivatives and substituted azaheterocyclecarboxylic acids. These compounds exhibit excellent substance P antagonistic activity, making them useful for treating various conditions such as gastrointestinal disorders, central nervous system disorders, allergies, inflammatory diseases, asthma, pain, emesis, and migraines in mammals, especially humans. Notable examples of his patented compounds include (2S*,3S*,4R*,5R*)-4-Carboxy-3-[N-(5-Isopropyl-2-methoxy-benzyl)amino]-5-methyl-2-phenylpyrrolidine and (2S*,3S*,5S*)-5-Carboxy-3-[N-(2-methoxy-5-trifluoromethoxybenzyl)amino]-2-phenylpiperidine.

Career Highlights

Throughout his career, Nakane has worked with leading pharmaceutical companies, including Pfizer Corporation. His innovative research has led to advancements in drug development and therapeutic solutions.

Collaborations

Masami Nakane has collaborated with notable colleagues such as Fumitaka Ito and Kunio Satake. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in pharmaceutical chemistry.

Conclusion

Masami Nakane's contributions to the field of pharmaceutical chemistry are noteworthy, with a focus on developing innovative compounds for medical treatment. His work continues to influence the industry and improve patient outcomes.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]